Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza VaccineCompleted
NCT03391193Phase 3Updated Apr 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
Mexico
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mLCompleted
NCT03406000Phase 4Updated Apr 25, 2022
Sponsor: Sanofi
Type I Diabetes Mellitus
Brazil
Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in VietnamCompleted
NCT03765437Phase 3Updated Apr 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
Vietnam
A Drug to Drug Interaction Study of Sotagliflozin With HydrochlorothiazideCompleted
NCT03387657Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)Completed
NCT03767543Phase 3Updated Apr 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
Canada
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female SubjectsCompleted
NCT03681158Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Epilepsy
United Kingdom
Zika Case Definition and Surveillance StudyCompleted
NCT03158233N/AUpdated Apr 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Zika Virus Disease
Colombia, Honduras, Mexico, Puerto Rico
Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes MellitusCompleted
NCT03462017Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Microvascular Coronary Artery Disease
Germany
Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of InsulinCompleted
NCT03760991Phase 4Updated Apr 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
Argentina, Colombia, Egypt, Hong Kong, India +9 more
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)Completed
NCT02836704Phase 4Updated Apr 25, 2022
Sponsor: Sanofi
Diabetes Mellitus, Type 2
China
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple MyelomaCompleted
NCT02514668Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Plasma Cell Myeloma
United States, Czechia, France
A Drug-Drug Interaction Study Between Sotagliflozin and RamiprilCompleted
NCT03414723Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Diabetes Mellitus · Healthy Subjects
Germany
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanCompleted
NCT02941367Phase 4Updated Apr 25, 2022
Sponsor: Sanofi
Diabetes Mellitus, Type 2
India, Israel, Kuwait, Turkey (Türkiye)
Sotagliflozin Bioequivalence StudyCompleted
NCT03211195Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States
Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep DisordersCompleted
NCT03514732Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Sleep Disorder (Healthy Volunteers)
Poland
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney TransplantCompleted
NCT03099122Phase 4Updated Apr 25, 2022
Sponsor: Sanofi
End-stage Renal Disease
China
A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple SclerosisCompleted
NCT02977533Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Progressive Multiple Sclerosis
Germany
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without SulfonylureaTerminated
NCT03761134Phase 3Updated Apr 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
China
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)Completed
NCT02545842Phase 4Updated Apr 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
China
Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute PharyngitisCompleted
NCT03583658Phase 3Updated Apr 25, 2022
Sponsor: Sanofi
Pharyngitis
South Africa
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis VaccinesCompleted
NCT01129362N/AUpdated Apr 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Pertussis
United States
Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis RegimenCompleted
NCT01622062Phase 3Updated Apr 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Rabies
Philippines
Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue VaccineCompleted
NCT02827162N/AUpdated Apr 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Haemorrhagic Fever
Thailand
Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of PollutantsCompleted
NCT03664882Phase 3Updated Apr 25, 2022
Sponsor: Sanofi
Rhinitis Seasonal
Canada
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated DisordersCompleted
NCT02502903Phase 1Updated Apr 25, 2022
Sponsor: Bioverativ, a Sanofi company
Bullous Pemphigoid (BP) · Cold Agglutinin Disease (CAD) · Warm Autoimmune Hemolytic Anemia (WAIHA) · End-stage Renal Disease (ESRD)
Austria

Previous page Next page